Tianjin Zhong Xin Pharmaceutical Group Corporation Limited
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People's Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and… Read more
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) - Net Assets
Latest net assets as of June 2025: €8.80 Billion EUR
Based on the latest financial reports, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) has net assets worth €8.80 Billion EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€12.85 Billion) and total liabilities (€4.05 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €8.80 Billion |
| % of Total Assets | 68.47% |
| Annual Growth Rate | 10.66% |
| 5-Year Change | 31.93% |
| 10-Year Change | 91.22% |
| Growth Volatility | 10.15 |
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited - Net Assets Trend (2013–2024)
This chart illustrates how Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2013–2024)
The table below shows the annual net assets of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €7.85 Billion | +18.13% |
| 2023-12-31 | €6.65 Billion | +1.42% |
| 2022-12-31 | €6.55 Billion | +0.59% |
| 2021-12-31 | €6.51 Billion | +9.48% |
| 2020-12-31 | €5.95 Billion | +7.73% |
| 2019-12-31 | €5.52 Billion | +9.28% |
| 2018-12-31 | €5.05 Billion | +9.27% |
| 2017-12-31 | €4.63 Billion | +7.51% |
| 2016-12-31 | €4.30 Billion | +4.80% |
| 2015-12-31 | €4.11 Billion | +39.32% |
| 2014-12-31 | €2.95 Billion | +14.43% |
| 2013-12-31 | €2.57 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 403.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €5.64 Billion | 71.84% |
| Other Components | €2.21 Billion | 28.16% |
| Total Equity | €7.84 Billion | 100.00% |
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Competitors by Market Cap
The table below lists competitors of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Anhui Wanwei Updated High-tech Material Industry Co Ltd
SHG:600063
|
$1.22 Billion |
|
Auren Energia S.A.
SA:AURE3
|
$1.22 Billion |
|
Beijing Lanxum Tech Co
SHE:300010
|
$1.22 Billion |
|
Isiklar Enerji ve Yapi Holding AS
IS:IEYHO
|
$1.22 Billion |
|
Farasis Energy Gan Zhou Co Ltd
SHG:688567
|
$1.22 Billion |
|
ProPetro Holding Corp
NYSE:PUMP
|
$1.22 Billion |
|
WALLENSTAM AB SER.B
F:WAE
|
$1.22 Billion |
|
Hangzhou Robam Appliances Co Ltd
SHE:002508
|
$1.22 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,600,690,543 to 7,843,592,379, a change of 1,242,901,836 (18.8%).
- Net income of 2,229,334,236 contributed positively to equity growth.
- Dividend payments of 1,010,588,612 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €2.23 Billion | +28.42% |
| Dividends Paid | €1.01 Billion | -12.88% |
| Other Changes | €24.16 Million | +0.31% |
| Total Change | €- | 18.83% |
Book Value vs Market Value Analysis
This analysis compares Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.27x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.48x to 0.27x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €5.82 | €2.79 | x |
| 2018-12-31 | €6.41 | €2.79 | x |
| 2019-12-31 | €7.01 | €2.79 | x |
| 2020-12-31 | €7.51 | €2.79 | x |
| 2021-12-31 | €8.23 | €2.79 | x |
| 2022-12-31 | €8.43 | €2.79 | x |
| 2023-12-31 | €16.50 | €2.79 | x |
| 2024-12-31 | €10.18 | €2.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tianjin Zhong Xin Pharmaceutical Group Corporation Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 28.42%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 30.51%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 1.37x
- Recent ROE (28.42%) is above the historical average (13.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 14.55% | 5.85% | 1.14x | 2.18x | €110.06 Million |
| 2014 | 12.95% | 5.05% | 1.30x | 1.97x | €81.42 Million |
| 2015 | 11.51% | 6.38% | 1.17x | 1.55x | €59.27 Million |
| 2016 | 10.20% | 6.84% | 0.97x | 1.54x | €8.46 Million |
| 2017 | 10.63% | 8.37% | 0.86x | 1.48x | €28.40 Million |
| 2018 | 11.40% | 8.83% | 0.89x | 1.44x | €68.98 Million |
| 2019 | 11.61% | 8.94% | 0.89x | 1.46x | €86.75 Million |
| 2020 | 11.39% | 10.02% | 0.80x | 1.43x | €80.86 Million |
| 2021 | 12.08% | 11.13% | 0.76x | 1.42x | €132.70 Million |
| 2022 | 13.21% | 10.45% | 0.81x | 1.56x | €209.65 Million |
| 2023 | 14.95% | 12.00% | 0.80x | 1.55x | €326.64 Million |
| 2024 | 28.42% | 30.51% | 0.68x | 1.37x | €1.44 Billion |
Industry Comparison
This section compares Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $11,237,553,108
- Average return on equity (ROE) among peers: -58.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | €8.80 Billion | 14.55% | 0.46x | $1.22 Billion |
| 26U (26U) | $45.60 Million | -9.53% | 0.22x | $234.57K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $3.44K |
| China Resources Pharmaceutical Group Limited (640) | $98.09 Billion | 3.42% | 1.63x | $887.95 Million |
| CIG WIRELESS (6CW) | $130.45 Million | -105.58% | 0.31x | $67.08 Million |
| Solasia Pharma K.K (9SO) | $2.66 Billion | -95.72% | 0.18x | $33.05 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $131.00 Million | -46.35% | 0.09x | $283.56 Million |
| Biofrontera AG (B8FK) | $7.38 Million | -176.58% | 6.65x | $3.69 Million |
| AVALA RES (CVJ) | $59.26 Million | -57.02% | 1.18x | $113.22K |